Professor Daniel C. Baumgart, MD PhD MBA FACP FRCP (Lon) AGAF


Department of Gastroenterology and Hepatology
Charité Medical Center - Virchow Hospital
Medical School of the Humboldt-University of Berlin
Augustenburger Platz 1
13353 Berlin

daniel.baumgart@charite.de

Deutsch

Biosketch

Daniel C. Baumgart, MD PhD MBA FACP FRCP (London) AGAF went to medical school in Berlin, Basel (Switzerland) and Wuerzburg (Bavaria). He received his training in internal medicine, gastroenterology, hepatology and immunology at the Charite and as a German Academic Exchange Service (DAAD) and German Research Foundation (DFG) scholar at the University of Pennsylvania, Philadelphia, PA, Georgetown University, Washington, DC, and the National Institutes of Health (NIH) Bethesda, MD, USA.
In 2017 he was appointed as University Professor and Director, Division of Gastroenterology, at the University of Alberta in Edmonton, Canada. In their 2022 Best Global Universities U.S. News & World Report ranked Gastroenterology and Hepatology as the No. 1 at the University of Alberta, No. 2 in Canada and No. 28 worldwide. Before he served as University Professor and Deputy Chief of the Department of Gastroenterology and Hepatology at Charite Medical School of the Humboldt-University of Berlin, and elected Fellow at the Berlin Institute of Health (BIH) endowed by the StiftungCharite foundation. He was Visiting Professor at Yale University, New Haven, CT and Harvard University, Boston, MA, USA.
Dr. Baumgart also directs the Inflammatory Bowel Disease Unit, is actively involved in the development of novel diagnostic and therapeutic concepts for Crohn’s disease and ulcerative colitis including new modalities of optical detection to visualize inflammation, mucosal damage and epithelial restitution and image guided intervention as discussed in his 2021 New England Journal of Medicine article. In a Nature Scientific Report his research group investigated how well several deep learning convolutional neural network architectures applied to the largest multi-class digestive image and video dataset available today diagnose and ulcerative colitis and assess disease severity. Dr. Baumgart has been principal investigator in some 200 multinational clinical trials and serves co-principal investigator in the Inflammation, Microbiome & Alimentation, Gastro-Intestinal & Neuropsychiatric Effects Specific Patient Oriented Research IMAGINE-SPOR Network funded by the Canadian Institutes of Health Research (CIHR).
A trailblazer of digital innovation, Adjunct University Professor of Computing Science, Faculty of Science, Department of Computing Science and member of the Precision Health and AI4Society Signature Areas he has a strong interest in digital health, artificial intelligence (AI) and decision support ultimately aiming to provide precision medicine at the point of care. In a Nature Digital Medicine article he describes how the pandemic accelerates digital innovation in medicine and healthcare. He chairs the Digestive Health Provincial Electronic Health Record (ConnectCare) Working Group and built the first Connect Care registry of all inflammatory bowel disease patients in Alberta. Dr. Baumgart is the principal investigator and program director of the „From Data to Decision (FD2D) - Digital Transformation and Artificial Intelligence from Data Value Chain to Human Value“ Collaborative Research and Training Experience (CREATE) program launched in 2022. It unites a multidisciplinary group of researchers and innovators at 22 leading academic institutions and technology companies in North America, Europe and Asia, that develop and study digital transformation and artificial intelligence applications across various academic disciplines and industrial sectors as well as their impact on society, funded by the Natural Sciences and Engineering Research Council of Canada (NSERC), Mathematics of Information Technology and Complex Systems (Mitacs) and the University of Alberta. Furthermore, his research in collaboration with the Alberta Machine Intelligence Institute, Kule Institute of Advanced Study (KIAS), and Alberta Health Services received grant support from the Canadian Institute of Advanced Research (CIFAR), Canadian Institutes of Health Research (CIHR), the Social Sciences and Humanities Research Council (SSHRC) and Alberta Innovates.
Dr. Baumgart has been serving on the editorial boards of leading medical and scientific journals including The Lancet, Gut and Inflammatory Bowel Diseases as well as on the executive of the Canadian IBD Research Consortium and the German IBD Competence Network and sits on various other international panels including the European Crohn’s and Colitis Organization.
A BMW Herbert Quandt Foundation responsible leadership alumnus he developed an innovative integrated clinical and research training curriculum for academic physicians, that received numerous awards including the VolkswagenStiftung foundation's Off the Beaten Track award for its extraordinary design and visionary impetus to academia and has been approved by the German Research Foundation (DFG), Federal Ministry for Education and Research (BMBF), the German Council of Science and Humanities (WR) and adopted by German medical schools nationwide.
In 2013 Dr. Baumgart was appointed fellow, American College of Physicians (FACP), Philadelphia; in 2014 fellow, American Gastroenterological Association (AGAF), Bethesda; and in 2017 Fellow of the Royal College of Physicians (FRCP), London, UK.

Major Clinical Interests


Inflammatory Bowel Disease (IBD) (Crohn’s Disease, Ulcerative Colitis, Fistulas, Pouchitis, Regional Enteritis, Ileitis, Ileocolitis), Celiac Disease (Non-Tropical Sprue, Gluten Enteropathy, Celiac Sprue), autoimmune enteropathy, enteral and parenteral nutrition, short bowel syndrome, immune deficiency disorders, immune defects, infections and other inflammatory disorders

Major Research Interests

Mucosal Immunology and Autoimmunity

Intestinal barrier, interaction of atypical (epithelial cells) and professional (dendritic cells) antigen presenting cells with microbial antigens of the microbiome, innate and adaptive immunity in infection and inflammation

Optical Detection und Imaging Guided Intervention

Lasermicroskopy, confocal microscopy, endocytoscopy, endoscopy, chromendoscopy, ultrasound (sonography), intestinal ultrasound, 3D and contract enhanced imaging and intervention, elastography

Personalized medicine in inflammatopry bowel disease

Immunomodulators, immunosuppressants, monoclonal antibodies, biologics, prebiotics, probiotics, antibiotics, adhesion molecule blockers, cell based immunotherapy, monoclonal antibodies against pro-inflammatory cytokines, fusion proteins, inhibitors of costimulatory molecules, prevention and management of malignant complications

Digital Innovation in Biomedical Research, Medicine and Healthcare   

Digital health, precision medicine, personalized medicine, artificial intelligence, AI, decision support, digitalization, digital transformation, algorithm, neural network, natural language processing, learning health system

Professional Membership

American Medical Association (AMA)
American Gastroenterological Association (AGA)
AGA Institute Council: Immunology, Microbiology & Inflammatory Bowel Disease & Gastrointestinal Oncology
American Society for Gastrointestinal Endoscopy (ASGE)
Canadian Medical Association (CMA) / Association Médicale Canadienne (CMA)
German Society for Gastroenterology and Metabolic Diseases (DGVS)
Gesellschaft für Gastroenterologie und Hepatologie in Berlin und Brandenburg e.V.
German Inflammatory Disease Network and Task Force (DACED)
German Inflammatory Bowel Disease Study Group Board (GISG)
European Crohn's and Colitis Organization (ECCO)
New Traditions Network (US Embassy and US Department of State)
Universities of the Future Project
German Academic Exchange Service (DAAD) Alumni Organization
Transatlantic Forum (Herbert Quandt Foundation)
World Young Leaders Forum
German University Professor Association (DHV)

Peer Review

Editorial Boards

Editorial Consultant at The Lancet
Member, Editorial Board: Gut
Section Editor: Inflammatory Bowel Diseases

Ad hoc reviewer for

Journals

Annals of the Rheumatic Diseases
British Journal of Surgery
Biomed Central
Clinical Gastroenterology and Hepatology
Clinical Pharmacology and Therapeutics
Deutsches Ärzteblatt (German Medical Weekly)
Digestive Surgery
Diseases of the Colon and Rectum
Drugs of Today
Endoscopy
European Journal of Pediatrics
European Journal of Gastroenterology and Hepatology
Expert Review of Gastroenterology and Hepatology
Expert Review of Molecular Diagnostics
Experimental Pharmacology
Future Drugs
Frontiers in Bioscience
Gastroenterology
Gastrointestinal Endoscopy
Gut
Human Immunology
Inflammatory Bowel Diseases
Immunobiology
Inflammopharmacology
JAMA (Journal of the American Medical Association)
Journal of Crohn’s and Colitis
Molecular Nutrition and Food Research
New England Journal of Medicine
Nutrition
Pediatrics
Pharmacogenomics
Recent Patents on Anti-Infective Drug Discovery
Recent Patents on Anti-Cancer Drug Discovery
Scandinavian Journal of Infectious Diseases
The American Journal of Clinical Dermatology
The American Journal of Gastroenterology
The American Journal of Physiology
The Journal of Immunology
The Journal of Clinical Investigation
The Lancet
The Lancet Infectious Diseases
The New England Journal of Medicine
Word Journal of Gastroenterology
Zeitschrift für Gastroenterologie

Institutions, Scientific Foundations and Grant und Funding Agencies

German Research Council (DFG)
Canadian Institutes of Health Research (CIHR)

Cochrane Library Special Interest Group Inflammatory Bowel Disease
The Wellcome Trust, London, UK
The Wellcome Trust, London, UK
The French National Research Agency / L'Agence nationale de la recherche (ANR), Paris, France
Health Research Board (An Bord Taighde Sláinte), Dublin, Ireland
AGA Institute Council: Immunology, Microbiology & Inflammatory Bowel Disease & Gastrointestinal Oncology, Bethesda, MD, USA
Biomedical Research Council and Ministry of Health's National Medical Research Council of Singapore
The Eli and Edythe L. Broad Foundation for IBD Research, Los Angeles, CA, USA
ZonMW (The Netherland Organisation für Health Research and Development), Den Haag, The Netherlands
FWF - Austrian Science Fund, Vienna, Austria
Israel Science Foundation (ISF), Jerusalem, Israel
United States-Israel Binational Science Foundation (BSF), Jerusalem, Israel
Academy of Finland (Suomen Akatemia, Terveyden tutkimuksen yksikkö), Helsiniki, Finland
Uni-Med Science Publishers, Boston, MA, USA
Drug Safety Institute, Miami, FL, USA

Publications

 

1             Baumgart DC, Gerl H, Dorner T. Complete heart block caused by primary Sjogren's syndrome and hypopituitarism. Ann Rheum Dis 1998;57:635.
2             Baumgart DC, McVay LD, Carding SR. Mechanisms of immune cell-mediated tissue injury in inflammatory bowel disease (Review). Int J Mol Med 1998;1:315-32.
3             Baumgart DC, Olivier WA, Reya T, Peritt D, Rombeau JL, Carding SR. Mechanisms of intestinal epithelial cell injury and colitis in interleukin 2 (IL2)-deficient mice. Cell Immunol 1998;187:52-66.
4             Baumgart DC, Ventz M, Wermke W. [18-year-old patient with hypercalcemia, hypophosphatemia, nephrocalcinosis and normal iPTH values. Primary hyperparathyroidism]. Internist (Berl) 1998;39:403-8.
5             Contractor NV, Bassiri H, Reya T, Park AY, Baumgart DC, Wasik MA, et al. Lymphoid hyperplasia, autoimmunity, and compromised intestinal intraepithelial lymphocyte development in colitis-free gnotobiotic IL-2-deficient mice. J Immunol 1998;160:385-94.
6             Macartney KK, Baumgart DC, Carding SR, Brubaker JO, Offit PA. Primary murine small intestinal epithelial cells, maintained in long-term culture, are susceptible to rotavirus infection. J Virol 2000;74:5597-603.
7             Telega GW, Baumgart DC, Carding SR. Uptake and presentation of antigen to T cells by primary colonic epithelial cells in normal and diseased states. Gastroenterology 2000;119:1548-59.
8             Baumgart DC, Dignass AU. [Intestinal gene regulation by commensal microflora. Remote control from within?]. Z Gastroenterol 2001;39:815-7.
9             Baumgart DC, Dignass AU. Intestinal barrier function. Curr Opin Clin Nutr Metab Care 2002;5:685-94.
10          Baumgart DC, Dignass AU. Shingles following infliximab infusion. Ann Rheum Dis 2002;61:661.
11          Baumgart DC, Dignass AU. [Mucosal dendritic cells: reaching out for the unknown (antigen)]. Z Gastroenterol 2002;40:375-7.
12          Baumgart DC, Dignass AU. [Tacrolimus (FK506) in refractory ulcerative colitis: an alternative to proctocolectomy?]. Z Gastroenterol 2003;41:478-9.
13          Baumgart DC, Gerl H. Photo quiz. Obesity and daytime sleepiness. Prader-Willi syndrome. Am Fam Physician 2003;68:151-2.
14          Baumgart DC, Wiedenmann B, Dignass AU. [Biologic therapy of inflammatory bowel disease]. Z Gastroenterol 2003;41:1017-32.
15          Baumgart DC, Wiedenmann B, Dignass AU. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther 2003;17:1273-81.
16          Baumgart DC, Dignass AU. Current biological therapies for inflammatory bowel disease. Curr Pharm Des 2004;10:4127-47.
17          Baumgart DC, Wiedenmann B, Dignass AU. Successful therapy of refractory pyoderma gangrenosum and periorbital phlegmona with tacrolimus (FK506) in ulcerative colitis. Inflamm Bowel Dis 2004;10:421-4.
18          Cruickshank SM, McVay LD, Baumgart DC, Felsburg PJ, Carding SR. Colonic epithelial cell mediated suppression of CD4 T cell activation. Gut 2004;53:678-84.
19          Dignass AU, Baumgart DC, Sturm A. Review article: the aetiopathogenesis of inflammatory bowel disease--immunology and repair mechanisms. Aliment Pharmacol Ther 2004;20 Suppl 4:9-17.
20          Baumgart DC. Personal digital assistants in health care: experienced clinicians in the palm of your hand? Lancet 2005;366:1210-22.
21          Baumgart DC, Metzke D, Schmitz J, Scheffold A, Sturm A, Wiedenmann B, et al. Patients with active inflammatory bowel disease lack immature peripheral blood plasmacytoid and myeloid dendritic cells. Gut 2005;54:228-36.
22          Baumgart DC, Sturm A, Wiedenmann B, Dignass AU. Uneventful pregnancy and neonatal outcome with tacrolimus in refractory ulcerative colitis. Gut 2005;54:1822-3.
23          Baumgart DC, Vierziger K, Sturm A, Wiedenmann B, Dignass AU. Mesalamine promotes intestinal epithelial wound healing in vitro through a TGF-beta-independent mechanism. Scand J Gastroenterol 2005;40:958-64.
24          Baumgart DCV-S, W.; Wiedenmann, B.; Hintze, R.E. Successful recanalization of a completely obliterated esophageal stricture by using an endoscopic rendezvous maneuver. Gastrointest Endosc 2005;61:473-5.
25          Baumgart DCV-S, W.; Wiedenmann, B. Successful recanalization of a completely obliterated esophageal stricture by using an endoscopic rendezvous maneuver. Gastrointest Endosc 2005;62:648.
26          Sturm A, Baumgart DC, d'Heureuse JH, Hotz A, Wiedenmann B, Dignass AU. CXCL8 modulates human intestinal epithelial cells through a CXCR1 dependent pathway. Cytokine 2005;29:42-8.
27          Sturm A, Rilling K, Baumgart DC, Gargas K, Abou-Ghazale T, Raupach B, et al. Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling. Infect Immun 2005;73:1452-65.
28          Andresen VB, D.C. Role of probiotics in the treatment of irritable bowel syndrome: potential mechanisms and current clinical evidence. International Journal of Probiotics & Prebiotics 2006;1:11-8.
29          Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up. Am J Gastroenterol 2006;101:1048-56.
30          Baumgart DCT, B.T., Dignass, A. Therapie chronisch-entzündlicher Darmerkrankungen mit Biologika und Immunmodulatoren. D Bay Int 2006;26:144-8.
31          Grabig A, Paclik D, Guzy C, Dankof A, Baumgart DC, Erckenbrecht J, et al. Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways. Infect Immun 2006;74:4075-82.
32          Tanczos BT, Baumgart DC. [Infliximab for the management of pyoderma gangrenosum in inflammatory bowel disease: one for all?]. Z Gastroenterol 2006;44:609-10.
33          Baumgart DC. Recognition and appropriate management of dysplasia-associated lesions or masses in inflammatory bowel disease--experience does matter. Gastrointest Endosc 2007;66:530-2.
34          Baumgart DC, Buning C, Geerdts L, Schmidt HH, Genschel J, Fiedler T, et al. The c.1-260C>T promoter variant of CD14 but not the c.896A>G (p.D299G) variant of toll-like receptor 4 (TLR4) genes is associated with inflammatory bowel disease. Digestion 2007;76:196-202.
35          Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007;369:1627-40.
36          Baumgart DC, Fischer A. Virchow's node. Lancet 2007;370:1568.
37          Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007;369:1641-57.
38          Buning C, Durmus T, Molnar T, de Jong DJ, Drenth JP, Fiedler T, et al. A study in three European IBD cohorts confirms that the ATG16L1 c.898A>G (p.Thr300Ala) variant is a susceptibility factor for Crohn's disease. J Crohns Colitis 2007;1:70-6.
39          Buning C, Schmidt HH, Molnar T, De Jong DJ, Fiedler T, Buhner S, et al. Heterozygosity for IL23R p.Arg381Gln confers a protective effect not only against Crohn's disease but also ulcerative colitis. Aliment Pharmacol Ther 2007;26:1025-33.
40          Schott E, Paul F, Wuerfel JT, Zipp F, Rudolph B, Wiedenmann B, et al. Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon beta 1a. World J Gastroenterol 2007;13:3638-40.
41          Weylandt KH, Kang JX, Wiedenmann B, Baumgart DC. Lipoxins and resolvins in inflammatory bowel disease. Inflamm Bowel Dis 2007;13:797-9.
42          Baumgart DC. What's new in inflammatory bowel disease in 2008? World J Gastroenterol 2008;14:329-30.
43          Baumgart DC, Macdonald JK, Feagan B. Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane Database Syst Rev 2008:CD007216.
44          Berndt U, Philipsen L, Bartsch S, Wiedenmann B, Baumgart DC, Hammerle M, et al. Systematic high-content proteomic analysis reveals substantial immunologic changes in colorectal cancer. Cancer Res 2008;68:880-8.
45          Buning C, Schmidt HH, Molnar T, Drenth JP, Fiedler T, Gentz E, et al. No association of the CARD8 (TUCAN) c.30T>A (p.C10X) variant with Crohn's disease: a study in 3 independent European cohorts. Inflamm Bowel Dis 2008;14:332-7.
46          Icks A, Kruse J, Dragano N, Broecker-Preuss M, Slomiany U, Mann K, et al. Are symptoms of depression more common in diabetes? Results from the Heinz Nixdorf Recall study. Diabet Med 2008;25:1330-6.
47          Niesner U, Albrecht I, Janke M, Doebis C, Loddenkemper C, Lexberg MH, et al. Autoregulation of Th1-mediated inflammation by twist1. J Exp Med 2008;205:1889-901.
48          Paul F, Pfueller CF, Wuerfel JT, Egerer K, Tanczos B, Baumgart DC, et al. Celiac antibodies in the diagnostic workup of white matter lesions. Neurology 2008;71:223-5.
49          Baumgart DC. The diagnosis and treatment of Crohn's disease and ulcerative colitis. Dtsch Arztebl Int 2009;106:123-33.
50          Baumgart DC, Lowder JN, Targan SR, Sandborn WJ, Frankel MB. Transient cytokine-induced liver injury following administration of the humanized anti-CD3 antibody visilizumab (HuM291) in Crohn's disease. Am J Gastroenterol 2009;104:868-76.
51          Baumgart DC, Thomas S, Przesdzing I, Metzke D, Bielecki C, Lehmann SM, et al. Exaggerated inflammatory response of primary human myeloid dendritic cells to lipopolysaccharide in patients with inflammatory bowel disease. Clin Exp Immunol 2009;157:423-36.
52          Habbel P, Weylandt KH, Lichopoj K, Nowak J, Purschke M, Wang JD, et al. Docosahexaenoic acid suppresses arachidonic acid-induced proliferation of LS-174T human colon carcinoma cells. World J Gastroenterol 2009;15:1079-84.
53          Hasper D, Schefold JC, Baumgart DC. Management of severe abdominal infections. Recent Pat Antiinfect Drug Discov 2009;4:57-65.
54          Pohl H, Rosch T, Tanczos BT, Rudolph B, Schluns K, Baumgart DC. Endocytoscopy for the detection of microstructural features in adult patients with celiac sprue: a prospective, blinded endocytoscopy-conventional histology correlation study. Gastrointest Endosc 2009;70:933-41.
55          Thomas S, Przesdzing I, Metzke D, Schmitz J, Radbruch A, Baumgart DC. Saccharomyces boulardii inhibits lipopolysaccharide-induced activation of human dendritic cells and T cell proliferation. Clin Exp Immunol 2009;156:78-87.
56          Baumgart DC. How many lives does an ulcerative colitis patient have? Lancet 2010;376:928.
57          Baumgart DC. CB-01-05-MMX, a novel oral controlled-release low molecular weight heparin for the potential treatment of ulcerative colitis. Curr Opin Investig Drugs 2010;11:571-6.
58          Baumgart DC. Veto on vedolizumab (MLN0002) for Crohn's disease. Inflamm Bowel Dis 2010;16:537-8.
59          Baumgart DC, Targan SR, Dignass AU, Mayer L, van Assche G, Hommes DW, et al. Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis 2010;16:620-9.
60          Muller T, Baumgart DC. [Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: the more the better?]. Z Gastroenterol 2010;48:569-70.
61          Sandborn WJ, Colombel JF, Frankel M, Hommes D, Lowder JN, Mayer L, et al. Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. Gut 2010;59:1485-92.
62          Schirbel A, Reichert A, Roll S, Baumgart DC, Buning C, Wittig B, et al. Impact of pain on health-related quality of life in patients with inflammatory bowel disease. World J Gastroenterol 2010;16:3168-77.
63          Van Assche G, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De Vos M, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis 2010;4:63-101.
64          Baumgart DC. Foreword. European Gastroenterology and Hepatology Review 2011;7:152-3.
65          Baumgart DC. Smartphones in clinical practice, medical education, and research. Arch Intern Med 2011;171:1294-6.
66          Baumgart DC. Extended colonic release low-molecular weight heparin (LMWH) not ready for use in ulcerative colitis. Evid Based Med 2011;16:71-2.
67          Baumgart DC. Endoscopic surveillance in Crohn's disease and ulcerative colitis: who needs what and when? Dig Dis 2011;29 Suppl 1:32-5.
68          Baumgart DC, Bernstein CN, Abbas Z, Colombel JF, Day AS, D'Haens G, et al. IBD Around the world: comparing the epidemiology, diagnosis, and treatment: proceedings of the World Digestive Health Day 2010--Inflammatory Bowel Disease Task Force meeting. Inflamm Bowel Dis 2011;17:639-44.
69          Baumgart DC, Grittner U, Steingraber A, Azzaro M, Philipp S. Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients. Inflamm Bowel Dis 2011;17:2512-20.
70          Baumgart DC, Metzke D, Guckelberger O, Pascher A, Grotzinger C, Przesdzing I, et al. Aberrant plasmacytoid dendritic cell distribution and function in patients with Crohn's disease and ulcerative colitis. Clin Exp Immunol 2011;166:46-54.
71          Eckardt AJ, Baumgart DC. Viral gastroenteritis in adults. Recent Pat Antiinfect Drug Discov 2011;6:54-63.
72          German IBDSG. [Adherence to the H1N1 vaccination recommendation in patients with Crohn's disease or ulcerative colitis]. Dtsch Med Wochenschr 2011;136:939-43.
73          Thomas S, Metzke D, Schmitz J, Dorffel Y, Baumgart DC. Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn's disease and ulcerative colitis. Am J Physiol Gastrointest Liver Physiol 2011;301:G1083-92.
74          Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012;366:601-9.
75          Autenrieth DM, Baumgart DC. Toxic megacolon. Inflamm Bowel Dis 2012;18:584-91.
76          Baumgart DC, Sandborn WJ. Crohn's disease. Lancet 2012;380:1590-605.
77          Buning C, Geissler N, Prager M, Sturm A, Baumgart DC, Buttner J, et al. Increased small intestinal permeability in ulcerative colitis: rather genetic than environmental and a risk factor for extensive disease? Inflamm Bowel Dis 2012;18:1932-9.
78          Louis E, Baumgart DC, Ghosh S, Gomollon F, Hanauer S, Hart A, et al. What changes in inflammatory bowel disease management can be implemented today? J Crohns Colitis 2012;6 Suppl 2:S260-7.
79          Ordas I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet 2012;380:1606-19.
80          Pohl H, Tanczos BT, Rudolph B, Meining A, Khalifa AC, Rosch T, et al. Probe-based confocal laser microscopy identifies criteria predictive of active celiac sprue. Dig Dis Sci 2012;57:451-7.
81          Prager M, Buttner J, Haas V, Baumgart DC, Sturm A, Zeitz M, et al. The JAK2 variant rs10758669 in Crohn's disease: altering the intestinal barrier as one mechanism of action. Int J Colorectal Dis 2012;27:565-73.
82          Prantera C, Lochs H, Grimaldi M, Danese S, Scribano ML, Gionchetti P, et al. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology 2012;142:473-81 e4.
83          Thomas S, Baumgart DC. Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis. Inflammopharmacology 2012;20:1-18.
84          Baumgart DC, Sandborn WJ. Erratum: Crohn's disease (The Lancet (2012) 380 (1590-605)). The Lancet 2013;381:204.
85          Fischer A, Gluth M, Pape UF, Wiedenmann B, Theuring F, Baumgart DC. Adalimumab prevents barrier dysfunction and antagonizes distinct effects of TNF-alpha on tight junction proteins and signaling pathways in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 2013;304:G970-9.
86          Kohnke T, Gomolka B, Bilal S, Zhou X, Sun Y, Rothe M, et al. Acetylsalicylic Acid reduces the severity of dextran sodium sulfate-induced colitis and increases the formation of anti-inflammatory lipid mediators. Biomed Res Int 2013;2013:748160.
87          Muller T, Beutler C, Pico AH, Otten M, Durr A, Al-Abadi H, et al. Increased T-helper 2 cytokines in bile from patients with IgG4-related cholangitis disrupt the tight junction-associated biliary epithelial cell barrier. Gastroenterology 2013;144:1116-28.
88          Panes J, Bouhnik Y, Reinisch W, Stoker J, Taylor SA, Baumgart DC, et al. Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. J Crohns Colitis 2013;7:556-85.
89          Pohl H, Wrobel K, Bojarski C, Voderholzer W, Sonnenberg A, Rosch T, et al. Risk factors in the development of esophageal adenocarcinoma. Am J Gastroenterol 2013;108:200-7.
90          Rutgeerts PJ, Fedorak RN, Hommes DW, Sturm A, Baumgart DC, Bressler B, et al. A randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis. Gut 2013;62:1122-30.
91          Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369:711-21.
92          Fischer A, Gluth M, Weege F, Pape UF, Wiedenmann B, Baumgart DC, et al. Glucocorticoids regulate barrier function and claudin expression in intestinal epithelial cells via MKP-1. Am J Physiol Gastrointest Liver Physiol 2014;306:G218-28.
93          Gerlach UA, Vrakas G, Reddy S, Baumgart DC, Neuhaus P, Friend PJ, et al. Chronic intestinal failure after Crohn disease: when to perform transplantation. JAMA Surg 2014;149:1060-6.
94          Papanikolaou IS, van der Voort IR, Chopra SS, Seebauer CJ, Rump J, Papas MG, et al. MRI-guided percutaneous transhepatic cholangiodrainage: feasibility study in a porcine model. Scand J Gastroenterol 2014;49:722-6.
95          Prager M, Durmus T, Buttner J, Molnar T, de Jong DJ, Drenth JP, et al. Myosin IXb variants and their pivotal role in maintaining the intestinal barrier: a study in Crohn's disease. Scand J Gastroenterol 2014;49:1191-200.
96          Vermeire S, O'Byrne S, Keir M, Williams M, Lu TT, Mansfield JC, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet 2014;384:309-18.
97          Baumgart DC. [The human microbiome]. Dtsch Med Wochenschr 2015;140:1451-6.
98          Baumgart DC, Muller HP, Grittner U, Metzke D, Fischer A, Guckelberger O, et al. US-based Real-time Elastography for the Detection of Fibrotic Gut Tissue in Patients with Stricturing Crohn Disease. Radiology 2015;275:889-99.
99          Gasche C, Ahmad T, Tulassay Z, Baumgart DC, Bokemeyer B, Buning C, et al. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program. Inflamm Bowel Dis 2015;21:579-88.
100        Krupka N, Baumgart DC. Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab. Drug Des Devel Ther 2015;9:147-54.
101        Baumgart DC, Bokemeyer B, Drabik A, Stallmach A, Schreiber S, Vedolizumab Germany C. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice--a nationwide consecutive German cohort study. Aliment Pharmacol Ther 2016;43:1090-102.
102        Baumgart DC, le Claire M. The Expenditures for Academic Inpatient Care of Inflammatory Bowel Disease Patients Are Almost Double Compared with Average Academic Gastroenterology and Hepatology Cases and Not Fully Recovered by Diagnosis-Related Group (DRG) Proceeds. PLoS One 2016;11:e0147364.
103        Baumgart DC, Wende I, Grittner U. Tablet computer-based multimedia enhanced medical training improves performance in gastroenterology and endoscopy board style exam compared with traditional medical education. Gut 2016;65:535-6.
104        Dignass A, Akbar A, Hart A, Subramanian S, Bommelaer G, Baumgart DC, et al. Safety and Efficacy of Granulocyte/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insufficient Response or Intolerance to Immunosuppressants and/or Biologics [the ART Trial]: 12-week Interim Results. J Crohns Colitis 2016;10:812-20.
105        Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med 2016;375:1946-60.
106        Panes J, Garcia-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet 2016;388:1281-90.
107        Regueiro M, Feagan BG, Zou B, Johanns J, Blank MA, Chevrier M, et al. Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. Gastroenterology 2016;150:1568-78.
108        Roggenbuck D, Reinhold D, Baumgart DC, Schierack P, Conrad K, Laass MW. Autoimmunity in Crohn's Disease-A Putative Stratification Factor of the Clinical Phenotype. Adv Clin Chem 2016;77:77-101.
109        Schmidt C, Ahmad T, Tulassay Z, Baumgart DC, Bokemeyer B, Howaldt S, et al. Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a Phase 3 study. Aliment Pharmacol Ther 2016;44:259-70.
110        Schmidt KJ, Muller N, Dignass A, Baumgart DC, Lehnert H, Stange EF, et al. Long-term Outcomes in Steroid-refractory Ulcerative Colitis Treated with Tacrolimus Alone or in Combination with Purine Analogues. J Crohns Colitis 2016;10:31-7.
111        Stallmach A, Langbein C, Atreya R, Bruns T, Dignass A, Ende K, et al. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study. Aliment Pharmacol Ther 2016;44:1199-212.
112        Teich N, Mohl W, Bokemeyer B, Bundgens B, Buning J, Miehlke S, et al. Azathioprine-induced Acute Pancreatitis in Patients with Inflammatory Bowel Diseases--A Prospective Study on Incidence and Severity. J Crohns Colitis 2016;10:61-8.
113        Tew GW, Hackney JA, Gibbons D, Lamb CA, Luca D, Egen JG, et al. Association Between Response to Etrolizumab and Expression of Integrin alphaE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis. Gastroenterology 2016;150:477-87 e9.
114        Autenrieth DM, Baumgart DC. [Microbiome and Gut Inflammation]. Dtsch Med Wochenschr 2017;142:261-6.
115        Baumgart DC, Wende I, Grittner U. Tablet computer enhanced training improves internal medicine exam performance. PLoS One 2017;12:e0172827.
116        Julsgaard M, Kjeldsen J, Baumgart DC. Vedolizumab safety in pregnancy and newborn outcomes. Gut 2017;66:1866-7.
117        Kucharzik T, Wittig BM, Helwig U, Borner N, Rossler A, Rath S, et al. Use of Intestinal Ultrasound to Monitor Crohn's Disease Activity. Clin Gastroenterol Hepatol 2017;15:535-42 e2.
118        Steinhagen PR, Baumgart DC. [Fundamentals of the microbiome]. Internist (Berl) 2017;58:429-34.
119        Authors, Collaborators. [Updated S3-Guideline Colitis ulcerosa. German Society for Digestive and Metabolic Diseases (DGVS) - AWMF Registry 021/009]. Z Gastroenterol 2018;56:1087-169.
120        Ciccocioppo R, Dos Santos CC, Baumgart DC, Cangemi GC, Cardinale V, Ciacci C, et al. Proceedings of the signature series event of the international society for cellular therapy: "Advancements in cellular therapies and regenerative medicine in digestive diseases," London, United Kingdom, May 3, 2017. Cytotherapy 2018;20:461-76.
121        D'Haens G, Vermeire S, Vogelsang H, Allez M, Desreumaux P, Van Gossum A, et al. Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating beta7+ T Cells in Crohn's Disease: Report of the TOSCA Study. J Crohns Colitis 2018;12:188-96.
122        Dignass A, Akbar A, Baumgart DC, Bommelaer G, Bouguen G, Cadiot G, et al. Granulocyte/monocyte adsorptive apheresis for the treatment of therapy-refractory chronic active ulcerative colitis. Scand J Gastroenterol 2018;53:442-8.
123        Domenech E, Panes J, Hinojosa J, Annese V, Magro F, Sturniolo GC, et al. Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial. J Crohns Colitis 2018;12:687-94.
124        Hudert CA, Tzschatzsch H, Guo J, Rudolph B, Blaker H, Loddenkemper C, et al. US Time-Harmonic Elastography: Detection of Liver Fibrosis in Adolescents with Extreme Obesity with Nonalcoholic Fatty Liver Disease. Radiology 2018;288:99-106.
125        Julsgaard M, Kjeldsen J, Bibby BM, Brock B, Baumgart DC. Vedolizumab Concentrations in the Breast Milk of Nursing Mothers With Inflammatory Bowel Disease. Gastroenterology 2018;154:752-4 e1.
126        Julsgaard M, Kjeldsen J, Brock B, Baumgart DC. Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease. Aliment Pharmacol Ther 2018;48:386-8.
127        Kopylov U, Verstockt B, Biedermann L, Sebastian S, Pugliese D, Sonnenberg E, et al. Effectiveness and Safety of Vedolizumab in Anti-TNF-Naive Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study. Inflamm Bowel Dis 2018;24:2442-51.
128        Mahadevan U, Dubinsky MC, Su C, Lawendy N, Jones TV, Marren A, et al. Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis. Inflamm Bowel Dis 2018;24:2494-500.
129        Mogl MT, Baumgart DC, Fischer A, Pratschke J, Pascher A. Immunosuppression following liver transplantation and the course of inflammatory bowel disease - a case control study. Z Gastroenterol 2018;56:117-27.
130        Panes J, Garcia-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, et al. Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease. Gastroenterology 2018;154:1334-42 e4.
131        Peyrin-Biroulet L, Baumgart DC, Armuzzi A, Gionchetti P, Sebastian S, Danese S, et al. Quality of Care in Ulcerative Colitis: A Modified Delphi Panel Approach. Dig Dis 2018;36:346-53.
132        Sowa M, Kolenda R, Baumgart DC, Pratschke J, Papp M, Tornai T, et al. Mucosal Autoimmunity to Cell-Bound GP2 Isoforms Is a Sensitive Marker in PSC and Associated With the Clinical Phenotype. Front Immunol 2018;9:1959.
133        Stein J, Haas JS, Ong SH, Borchert K, Hardt T, Lechat E, et al. Oral versus intravenous iron therapy in patients with inflammatory bowel disease and iron deficiency with and without anemia in Germany - a real-world evidence analysis. Clinicoecon Outcomes Res 2018;10:93-103.
134        Authors, Collaborators. Updated S3-Guideline Ulcerative Colitis. German Society for Digestive and Metabolic Diseases (DGVS). Z Gastroenterol 2019;57:162-241.
135        Baumgart DC, Misery L, Naeyaert S, Taylor PC. Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities? Front Pharmacol 2019;10:279.
136        Ciccocioppo R, Baumgart DC, Dos Santos CC, Galipeau J, Klersy C, Orlando G. Perspectives of the International Society for Cell & Gene Therapy Gastrointestinal Scientific Committee on the Intravenous Use of Mesenchymal Stromal Cells in Inflammatory Bowel Disease (PeMeGi). Cytotherapy 2019;21:824-39.
137        Kucharzik T, Dignass AU, Atreya R, Bokemeyer B, Esters P, Herrlinger K, et al. [August 2019 - AWMF-Registriernummer: 021-009]. Z Gastroenterol 2019;57:e1.
138        Kucharzik T, Dignass AU, Atreya R, Bokemeyer B, Esters P, Herrlinger K, et al. [August 2019 - AWMF-Registriernummer: 021-009]. Z Gastroenterol 2019;57:1321-405.
139        Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis 2019;13:144-64.
140        Petruo VA, Krauss E, Kleist A, Hardt J, Hake K, Peirano J, et al. Perceived distress, personality characteristics, coping strategies and psychosocial impairments in a national German multicenter cohort of patients with Crohn's disease and ulcerative colitis. Z Gastroenterol 2019;57:473-83.
141        Repici A, Coron E, Sharma P, Spada C, Di Leo M, Noble CL, et al. Improved high-quality colon cleansing with 1L NER1006 versus 2L polyethylene glycol+ascorbate or oral sulfate solution. Dig Liver Dis 2019;51:1671-7.
142        Sands BE, Peyrin-Biroulet L, Loftus EV, Jr., Danese S, Colombel JF, Toruner M, et al. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. N Engl J Med 2019;381:1215-26.
143        Sands BE, Sandborn WJ, Panaccione R, O'Brien CD, Zhang H, Johanns J, et al. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2019;381:1201-14.
144        Schreiber S, Baumgart DC, Drenth JPH, Filip RS, Clayton LB, Hylands K, et al. Colon cleansing efficacy and safety with 1 L NER1006 versus sodium picosulfate with magnesium citrate: a randomized phase 3 trial. Endoscopy 2019;51:73-84.
145        Sturm A, Maaser C, Calabrese E, Annese V, Fiorino G, Kucharzik T, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. J Crohns Colitis 2019;13:273-84.
146        Balram B, Joshi H, Wong K, Kroeker KI, Dieleman LA, Halloran BP, et al. Concomitant 5-Aminosalicylate Therapy in Moderate-to-Severe Ulcerative Colitis Patients Escalated to Infliximab Is Not Beneficial. Dig Dis Sci 2020.
147        Baumgart DC. Digital advantage in the COVID-19 response: perspective from Canada's largest integrated digitalized healthcare system. NPJ Digit Med 2020;3:114.
148        D'Amico F, Baumgart DC, Danese S, Peyrin-Biroulet L. Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management. Clin Gastroenterol Hepatol 2020;18:1663-72.
149        Kucharzik T, Dignass AU, Atreya R, Bokemeyer B, Esters P, Herrlinger K, et al. [Not Available]. Z Gastroenterol 2020;58:e241-e326.
150        Meng ZW, Baumgart DC. Darvadstrocel for the treatment of perianal fistulas in Crohn's disease. Expert Rev Gastroenterol Hepatol 2020;14:405-10.
151        Moens A, van der Woude CJ, Julsgaard M, Humblet E, Sheridan J, Baumgart DC, et al. Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. Aliment Pharmacol Ther 2020;51:129-38.
152        Sutton RT, Pincock D, Baumgart DC, Sadowski DC, Fedorak RN, Kroeker KI. An overview of clinical decision support systems: benefits, risks, and strategies for success. NPJ Digit Med 2020;3:17.
153        Baumgart DC, Le Berre C. Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease. N Engl J Med 2021;385:1302-15.
154        Julsgaard M, Baumgart DC, Baunwall SMD, Hansen MM, Grosen A, Bibby BM, et al. Vedolizumab clearance in neonates, susceptibility to infections and developmental milestones: a prospective multicentre population-based cohort study. Aliment Pharmacol Ther 2021.
155        Sandborn WJ, Feagan BG, D'Haens G, Wolf DC, Jovanovic I, Hanauer SB, et al. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2021;385:1280-91.
156        Schmidt C, Bachmann O, Baumgart DC, Goetz M, Drvarov O, Kucharzik TF, et al. [Position paper on endoscopic reporting in IBD]. Z Gastroenterol 2021.
157        Winthrop KL, Loftus EV, Baumgart DC, Reinisch W, Nduaka CI, Lawendy N, et al. Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme. J Crohns Colitis 2021;15:914-29.
158        Sutton RT, Zai͏̈ane OR, Goebel R, Baumgart DC. Artificial intelligence enabled automated diagnosis and grading of ulcerative colitis endoscopy images. 2022: https://www.nature.com/articles/s41598-022-06726-2

Books and Chapters

Medical English

P Gross, DC Baumgart. Medical English. Thieme, Stuttgart-New York, 3rd ed., 2002.

Medical English

P Gross,DC Baumgart. Medical English. Thieme, Stuttgart-New York, 4th ed., 2003.

Medical English

P Gross,DC Baumgart. Medical English. Thieme, Stuttgart-New York, 5th ed., 2006.

Medical English Japanese Edition

P Gross,DC Baumgart. Medical English. Ohmsha Publishers, Tokyo, 1st Japanese ed., 2007.

Anglais Médical

P. Gross, DC Baumgart. Medical English (Anglais médical). Paris, Vigot-Maloine Publishers, 1st French ed., 2008

Anglais Médical

P. Gross, DC Baumgart. Medical English (Anglais médical). Paris, Vigot-Maloine Publishers, 2. French ed., 2009

Harrison's

DC Baumgart, B Wiedenmann. German Edition: Harrison' Principles of Internal Medicine, 15th ed., 2002.
Chapter 33: Dysphagia
Chapter 34: Nausea, Vomiting and Indigestion
Chapter 35: Diarrhea and Constipation
Chapter 36: Weight Loss
Chapter 37: Gastrointestinal Bleeding
Chapter 38: Jaundice
Chapter 39: Abdominal Swelling and Ascites
Chapter 93: Endocrine Tumors of the Gastrointestinal Tract and the Pancreas

Harrison's

DC Baumgart, B Wiedenmann. German Edition: Harrison' Principles of Internal Medicine, 16th ed.,, 2005.
Chapter 33: Dysphagia
Chapter 34: Nausea, Vomiting and Indigestion
Chapter 35: Diarrhea and Constipation
Chapter 36: Weight Loss
Chapter 37: Gastrointestinal Bleeding
Chapter 38: Jaundice
Chapter 39: Abdominal Swelling and Ascites
Chapter 93: Endocrine Tumors of the Gastrointestinal Tract and the Pancreas

Harrisons's

DC Baumgart und B Wiedenmann. German Edition.: Harrison' Principles of Internal Medicine, 17th ed., 2008.
Chapter 38: Dysphagia
Chapter 39: Nausea, Vomiting and Indigestion
Chapter 40: Diarrhea and Constipation
Chapter 41: Weight Loss
Chapter 42: Gastrointestinal Bleeding
Chapter 43: Jaundice
Chapter 44: Abdominal Swelling and Ascites
Chapter 344: Endocrine Tumors of the Gastrointestinal Tract and the Pancreas

Biologische Therapie

DC Baumgart, AU Dignass. Etiopathogenesis, Genetics and Environmental Factors. In: Biologic Therapy of Inflammatory Bowel Disease. Ed. AU Dignass, Uni-Med Science Publishers, Bremen-Boston, 1st ed., 2004: 18-41.

Biologische Therapie

DC Baumgart, AU Dignass. Mechanisms of Biologic Therapies. In: Biologic Therapy of Inflammatory Bowel Disease. Ed. AU Dignass, Uni-Med Science Publishers, Bremen-Boston, 1st ed., 2004: 18-41.

Biologische Therapie

DC Baumgart, H Schulze, AU Dignass. Biologische Therapie der chronisch entzündlichen Darmerkrankungen. Ed. AU Dignass, Uni-Med Science Publishers, Bremen-Boston, 2. Auflage, 2010.

Biolologic Therapy

DC Baumgart. Biologic Therapy for Inflammatory Bowel Diseases. Uni-Med Science Publishers, Bremen-Boston, 1st. ed. 2010.

Controversies in IBD

DC Baumgart. Refractory ulcerative colitis: is surgery always indicated? In: Trends and Controversies in IBD: Evidence-Based Approach or Individual Management? In: Trends and Controversies in Inflammatory Bowel Disease. Eds. Dignass AU, Lochs H, Stange EF. Springer Netherland, 1st ed., 2004.

Enddarm

DC Baumgart, B Wiedenmann. Gastroenterology and Hepatology: Diseases of the Colon and Rectum. In: Internal Medicine - essentials. Eds.. Lehnert H, Werdan K. Thieme, Stuttgart, 4th ed., 2005: 205-214.

Novel Therapies in IBD

DC Baumgart. Novel Therapies in IBD: T-cell modulating antibodies. In: Immunoregulation in Inflammatory Bowel Diseases - Current Understanding and Innovation. Eds. Dignass A, Rachmilewitz D, Stange EF, Weinstock JV. Springer, Berlin-New York, 1st ed., 2007: 194-201.

Innere Medizin

DC Baumgart, B Wiedenmann. Short bowel syndrome and small bowel transplantation. In: Internal Medicine. Eds. Classen M, Diehl V, Kochsiek K, Böhm B, Schmiegel W. Elsevier, Munich, 6th ed., 2009.

Praktische Gastroenterologie

DC Baumgart. Small bowel transplantation. In: Practical Gastroenterology. Eds. Layer P, Rosien U. Urban & Fischer Publishers. 3rd ed. 2008.

Praktische Gastroenterologie

Keller J, DC Baumgart. Short bowel syndrome. In: Practical Gastroenterology. Eds. Layer P, Rosien U. Urban & Fischer Publishers, 3rd ed., 2008.

Praktische Gastroenterologie

DC Baumgart, Rosien U. Gastroenterological complications following hematopoietic stem cell transplantation. In: Practical Gastroenterology. Eds. Layer P, Rosien U. Urban & Fischer Publishers, 4th ed. 2011.

Praktische Gastroenterologie

DC Baumgart. Small bowel transplantation. In: Practical Gastroenterology. Eds. Layer P, Rosien U. Urban & Fischer Publishers. 4th ed. 2011.

Praktische Gastroenterologie

Keller J, DC Baumgart. Short bowel syndrome. In: Practical Gastroenterology. Eds. Layer P, Rosien U. Urban & Fischer Publishers, 4th ed., 2011.

Praktische Gastroenterologie

DC Baumgart, Rosien U. Gastroenterological complications following hematopoietic stem cell transplantation. In: Practical Gastroenterology. Eds. Layer P, Rosien U. Urban & Fischer Publishers, 4th ed. 2011

Crohn's Disease and Ulcerative Colitis: From Epidemiology and Immunobiology to a Rational Diagnostic and Therapeutic Approach

DC Baumgart. Crohn's Disease and Ulcerative Colitis: From Epidemiology and Immunobiology to a Rational Diagnostic and Therapeutic Approach. Springer, New York, 1st ed. 2012

Fischer A, Baumgart DC. Tacrolimus, Sirolimus and Mycophenolate Mofetil. In: Medical Therapy of Ulcerative Colitis. Ed. Lichtenstein G. Springer New York 1. Auflage 2015